News Articles | Pfizer Singapore

Biopharma Leaders Unite To Stand With Science

Pfizer & BioNTech to Supply Singapore with Vaccine Candidate to Combat COVID-19

PFIZER INVESTS $120MIL IN BIOTECH INNOVATION

Pfizer Confirms U.S. Patent Term Extension for IBRANCE® (palbociclib) Until March 2027

AGREEMENT REACHED WITH COVAX FOR ADVANCE PURCHASE OF COVID-19 VACCINE

RECENT PRESS RELEASES

15/09/2020 - Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas

14/09/2020 - Pfizer Hosts Virtual Investor Day

12/09/2020 - Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial

11/09/2020 - Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

10/09/2020 - Pfizer to Present Latest Scientific Advancements from Its Industry-Leading Portfolio at the ESMO Virtual Congress 2020

09/09/2020 - Pfizer and BioNTech Announce Data from Preclinical Studies of mRNA-based Vaccine Candidate Against COVID-19

09/09/2020 - Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2

08/09/2020 - Biopharma Leaders Unite To Stand With Science

03/09/2020 - Pfizer Invites Public to Register for Webcast of Virtual Investor Day on September 14 and 15, 2020

21/08/2020 - Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19

07/08/2020 - Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-19

06/08/2020 - Pfizer Announces Times for Rescheduled Virtual Investor Day on September 14 and September 15, 2020

05/08/2020 - LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer

05/08/2020 - Pfizer and BioNTech to Supply Canada with their BNT162 mRNA- Based Vaccine Candidate

31/07/2020 - Pfizer and BioNTech to Supply Japan with 120 Million Doses of their BNT162 mRNA-based Vaccine Candidate